These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 12373075)

  • 1. Effect of relaxin in two models of renal mass reduction.
    Garber SL; Mirochnik Y; Brecklin C; Slobodskoy L; Arruda JA; Dunea G
    Am J Nephrol; 2003; 23(1):8-12. PubMed ID: 12373075
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Protective effects of relaxin against cisplatin-induced nephrotoxicity in rats.
    Yoshida T; Kumagai H; Kohsaka T; Ikegaya N
    Nephron Exp Nephrol; 2014; 128(1-2):9-20. PubMed ID: 25403022
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The anti-fibrotic hormone relaxin is not reno-protective, despite being active, in an experimental model of type 1 diabetes.
    Wong SE; Samuel CS; Kelly DJ; Zhang Y; Becker GJ; Hewitson TD
    Protein Pept Lett; 2013 Sep; 20(9):1029-38. PubMed ID: 23343143
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relaxin-mediated renal vasodilation in the rat is associated with falls in glomerular blood pressure.
    Deng A; Conrad K; Baylis C
    Am J Physiol Regul Integr Comp Physiol; 2018 Feb; 314(2):R147-R152. PubMed ID: 29046312
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relaxin-1-deficient mice develop an age-related progression of renal fibrosis.
    Samuel CS; Zhao C; Bond CP; Hewitson TD; Amento EP; Summers RJ
    Kidney Int; 2004 Jun; 65(6):2054-64. PubMed ID: 15149318
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relaxin decreases renal interstitial fibrosis and slows progression of renal disease.
    Garber SL; Mirochnik Y; Brecklin CS; Unemori EN; Singh AK; Slobodskoy L; Grove BH; Arruda JA; Dunea G
    Kidney Int; 2001 Mar; 59(3):876-82. PubMed ID: 11231342
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relaxin protects against renal ischemia-reperfusion injury.
    Yoshida T; Kumagai H; Kohsaka T; Ikegaya N
    Am J Physiol Renal Physiol; 2013 Oct; 305(8):F1169-76. PubMed ID: 23946288
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Protective role of relaxin in a mouse model of aristolochic acid nephropathy.
    Yang X; Thorngren D; Chen Q; Wang M; Xie X
    Biomed Pharmacother; 2019 Jul; 115():108917. PubMed ID: 31060002
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relaxin Attenuates Organ Fibrosis
    Barsha G; Walton SL; Kwok E; Mirabito Colafella KM; Pinar AA; Hilliard Krause LM; Gaspari TA; Widdop RE; Samuel CS; Denton KM
    Kidney360; 2021 Nov; 2(11):1781-1792. PubMed ID: 35373008
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Endogenous relaxin is a naturally occurring modulator of experimental renal tubulointerstitial fibrosis.
    Hewitson TD; Mookerjee I; Masterson R; Zhao C; Tregear GW; Becker GJ; Samuel CS
    Endocrinology; 2007 Feb; 148(2):660-9. PubMed ID: 17095590
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relaxin Ameliorates Renal Fibrosis and Expression of Endothelial Cell Transition Markers in Rats of Isoproterenol-Induced Heart Failure.
    Zheng G; Cai J; Chen X; Chen L; Ge W; Zhou X; Zhou H
    Biol Pharm Bull; 2017; 40(7):960-966. PubMed ID: 28674260
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relaxin is a potent renal vasodilator in conscious rats.
    Danielson LA; Sherwood OD; Conrad KP
    J Clin Invest; 1999 Feb; 103(4):525-33. PubMed ID: 10021461
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evolution of experimentally induced papillary necrosis to focal segmental glomerulosclerosis and nephrotic proteinuria.
    Garber SL; Mirochnik Y; Arruda JA; Dunea G
    Am J Kidney Dis; 1999 Jun; 33(6):1033-9. PubMed ID: 10352190
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Relaxin ameliorates salt-sensitive hypertension and renal fibrosis.
    Yoshida T; Kumagai H; Suzuki A; Kobayashi N; Ohkawa S; Odamaki M; Kohsaka T; Yamamoto T; Ikegaya N
    Nephrol Dial Transplant; 2012 Jun; 27(6):2190-7. PubMed ID: 22086971
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relaxin inhibits cardiac fibrosis and endothelial-mesenchymal transition via the Notch pathway.
    Zhou X; Chen X; Cai JJ; Chen LZ; Gong YS; Wang LX; Gao Z; Zhang HQ; Huang WJ; Zhou H
    Drug Des Devel Ther; 2015; 9():4599-611. PubMed ID: 26316699
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Acute treatment with relaxin attenuates the injury/dysfunction induced by renal ischemia/reperfusion injury.
    Collino M; Rogazzoi M; Pini A; Benetti E; Rosa AC; Fantozzi R; Bani D; Masini E
    Ital J Anat Embryol; 2013; 118(1 Suppl):74-6. PubMed ID: 24640578
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relaxin reduces susceptibility to post-infarct atrial fibrillation in mice due to anti-fibrotic and anti-inflammatory properties.
    Beiert T; Tiyerili V; Knappe V; Effelsberg V; Linhart M; Stöckigt F; Klein S; Schierwagen R; Trebicka J; Nickenig G; Schrickel JW; Andrié RP
    Biochem Biophys Res Commun; 2017 Aug; 490(3):643-649. PubMed ID: 28634079
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chronic lower-dose relaxin administration protects from arrhythmia in experimental myocardial infarction due to anti-inflammatory and anti-fibrotic properties.
    Beiert T; Knappe V; Tiyerili V; Stöckigt F; Effelsberg V; Linhart M; Steinmetz M; Klein S; Schierwagen R; Trebicka J; Roell W; Nickenig G; Schrickel JW; Andrié RP
    Int J Cardiol; 2018 Jan; 250():21-28. PubMed ID: 29169754
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Protective effects of relaxin in ischemia/reperfusion-induced intestinal injury due to splanchnic artery occlusion.
    Masini E; Cuzzocrea S; Mazzon E; Muià C; Vannacci A; Fabrizi F; Bani D
    Br J Pharmacol; 2006 Aug; 148(8):1124-32. PubMed ID: 16847443
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Protection from Cigarette Smoke-Induced Lung Dysfunction and Damage by H2 Relaxin (Serelaxin).
    Pini A; Boccalini G; Lucarini L; Catarinicchia S; Guasti D; Masini E; Bani D; Nistri S
    J Pharmacol Exp Ther; 2016 Jun; 357(3):451-8. PubMed ID: 27048661
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.